Literature DB >> 10447321

Chlamydial antibodies in an elderly Finnish population.

A L Koivisto1, R Isoaho, L Von Hertzen, M Töyrylä, P Laippala, S L Kivelä, P Saikku.   

Abstract

The characteristic feature of Chlamydia is its tendency to cause chronic infections. It has been hypothesized that prior exposure to C. pneumoniae may lead to chronic infection and the development of associated chronic cardiopulmonary disease. Few studies have so far addressed the occurrence of chlamydial antibodies in an elderly, unselected population. This information is important for the development of possible treatment strategies. Chlamydial antibodies were analysed from 1179 serum samples obtained from 481 men and 698 women, aged 64 y and over, who participated in an epidemiological survey carried out in a Finnish rural district. Specific IgG and IgA antibodies were measured by the microimmunofluorescence (micro-IF) test. The criterion for seropositivity was defined as a titre of > or =32 for both IgG and IgA, independently of each other. C. pneumoniae IgG antibodies occurred in 91% of the men and 75% of the women. The respective figures for C. pneumoniae IgA antibodies were 57% and 28%. The geometric mean titres (GMT) rose with increasing age and were higher in men than in women. The prevalences of C. trachomatis IgG antibodies were 13% in men and 18% in women, and for IgA antibodies, 2% and 1%, respectively. C. psittaci antibodies were rare. Only 3% of the men and women were IgG seropositive, whereas the respective figures for IgA seropositivity were 0.4% and 0.1%. C. pneumoniae antibodies indicative of recurrent or chronic infection were common in the elderly. The geometric mean titres correlated positively with age and were higher in men than in women. Other chlamydial antibodies occurred in low titres.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447321     DOI: 10.1080/003655499750006164

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  7 in total

1.  Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals.

Authors:  A Schumacher; A B Lerkerød; I Seljeflot; L Sommervoll; I Holme; J E Otterstad; H Arnesen
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

2.  Prevalence and persistence of Chlamydia pneumoniae antibodies in healthy laboratory personnel in Finland.

Authors:  Mika Paldanius; Aini Bloigu; Marianne Alho; Maija Leinonen; Pekka Saikku
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

3.  Detection of Helicobacter pylori and Chlamydia pneumoniae genes in primary orbital lymphoma.

Authors:  Chi-Chao Chan; Defen Shen; Manabu Mochizuki; John A Gonzales; Hunter K L Yuen; Yan Guex-Crosier; Phuc Lehoang
Journal:  Trans Am Ophthalmol Soc       Date:  2006

4.  Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study.

Authors:  Siobhan Sutcliffe; Edward Giovannucci; Charlotte A Gaydos; Raphael P Viscidi; Frank J Jenkins; Jonathan M Zenilman; Lisa P Jacobson; Angelo M De Marzo; Walter C Willett; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-08       Impact factor: 4.254

Review 5.  Chlamydial infection: the link with ocular adnexal lymphomas.

Authors:  Andrés J M Ferreri; Riccardo Dolcetti; Simone Magnino; Claudio Doglioni; Maurilio Ponzoni
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

6.  Evaluation of the level of antibodies against Chlamydophila (Chlamydia) pneumoniae in post-surgery heart ischaemia patients and their clinical conditions - a six-year study.

Authors:  Mirosław Brykczyński; Andrzej Zych; Iwona Gorący; Iwona Mączyńska; Iwona Wojciechowska-Koszko; Krzysztof Mokrzycki; Stefania Giedrys-Kalemba; Piotr Sielicki
Journal:  Arch Med Sci       Date:  2010-04-30       Impact factor: 3.318

7.  A retrospective seroepidemiologic survey of Chlamydia pneumoniae infection in patients in Beijing between 2008 and 2017.

Authors:  Jingtao Cui; Wenjuan Yan; Hongjie Xie; Shaoxia Xu; Qiaofeng Wang; Weihong Zhang; Anping Ni
Journal:  PLoS One       Date:  2018-11-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.